Pfizer Inc. announced last week that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The treatment includes nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer's laboratories, which was specifically designed to block the activity of the SARS-CoV-2 Mpro, an enzyme that the coronavirus needs to replicate.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.88 USD | +1.31% |
|
+4.92% | +3.32% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.32% | 167B | |
+56.95% | 848B | |
+31.64% | 627B | |
-0.06% | 363B | |
+15.42% | 318B | |
+12.50% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.32% | 179B | |
+2.52% | 125B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer Inc. Announces U.S. Food and Drug Administration Authorized Emergency Use of PAXLOVID